fotemustine has been researched along with Thrombocytopenia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 10 (50.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buonerba, C; Cerbone, L; Cordua, N; De Placido, S; Di Lorenzo, G; Lamberti, G; Marinelli, A; Peluso, G | 1 |
| Chi, ZH; Cui, CL; Guo, J; Lian, HY; Si, L; Yuan, XQ | 1 |
| Carapella, CM; Carosi, M; Cognetti, F; Fabi, A; Jandolo, B; Maschio, M; Metro, G; Mirri, MA; Pace, A; Russillo, M; Sperduti, I; Telera, S; Vidiri, A | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Baruchel, S; Bouffet, E; Gammon, J; Grant, RM; Hargrave, DR; Tariq, N | 1 |
| Ardiet, C; Berger, E; Bouafia, F; Coiffier, B; Dumontet, C; Guyotat, D; Jaubert, J; Lucas, C; Sebban, C; Tranchand, B | 1 |
| Clerico, MA; Marinozzi, C; Sozzi, P; Turrisi, G | 1 |
| A'Hern, R; Atkinson, H; Chang, J; Gore, ME; Lorentzos, A | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Allen, R; Berille, J; Rudd, R; Souhami, RL; Spiro, SG; Trask, C | 1 |
| Lee, SM; Margison, GP; Thatcher, N; Woodcock, AA | 1 |
| Boaziz, C; Coste, M; Haon, C; Raymond, E | 1 |
| Breitbart, E; Makki, A; Mohr, P; Schadendorf, D | 1 |
| Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
| Bourg, V; Chichmanian, RM; Frenay, M; Lebrun, C; Thomas, P | 1 |
| Avril, MF; Bonneterre, J; Cupissol, D; Fargeot, P; Fumoleau, P; Grob, JJ; Israel, L; Kalis, B; Kerbrat, P; Lambert, D | 1 |
| Binder, M; Dorffner, R; Glebowski, E; Pehamberger, H; Winkler, A; Wolff, K | 1 |
| Crowther, D; Kerbrat, P; Lentz, MA; Mouridsen, HT; Santoro, A; Somers, R; Steward, WP; Tursz, T; van Glabbeke, M; Verweij, J | 1 |
| Cour, V; Fety, R; Lucas, C; Solere, P; Vignoud, J | 1 |
| Banzet, P; Bizzari, JP; Jacquillat, C; Khayat, D; Lokiec, F; Meeus, L; Rouesse, J; Sellami, M; Weil, M | 1 |
1 review(s) available for fotemustine and Thrombocytopenia
| Article | Year |
|---|---|
Logistic regression model of fotemustine toxicity combining independent phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Female; Humans; Leukopenia; Logistic Models; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia | 1996 |
12 trial(s) available for fotemustine and Thrombocytopenia
| Article | Year |
|---|---|
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Glioblastoma; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Thrombocytopenia | 2018 |
[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokine-Induced Killer Cells; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatic Artery; Humans; Immunotherapy, Adoptive; Infusions, Intra-Arterial; Interleukin-2; Liver Neoplasms; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Remission Induction; Survival Rate; Thrombocytopenia; Young Adult | 2008 |
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Topics: Adolescent; Anemia; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Female; Humans; Infant; Injections, Intravenous; Male; Medulloblastoma; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Sarcoma; Thrombocytopenia; Treatment Outcome | 2002 |
Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.
Topics: Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Outpatients; Prognosis; Recurrence; Sepsis; Thrombocytopenia | 2003 |
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Outcome | 1994 |
Phase II trial of fotemustine in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia; Treatment Failure | 1994 |
Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Quality of Life; Thrombocytopenia | 1994 |
Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Respiratory Distress Syndrome; Thrombocytopenia | 1993 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Drug Administration Schedule; Humans; Leukopenia; Melanoma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Skin Neoplasms; Thrombocytopenia | 1998 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |
Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukopenia; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia | 1992 |
7 other study(ies) available for fotemustine and Thrombocytopenia
| Article | Year |
|---|---|
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents; DNA Methylation; Dose-Response Relationship, Drug; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Middle Aged; Multivariate Analysis; Nausea; Neoplasm Recurrence, Local; Neutropenia; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |
Persistent thrombocytopenia during melanoma treatment with fotemustine.
Topics: Aged; Antineoplastic Agents; Humans; Male; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 2006 |
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Drug Interactions; Epilepsy; Etoposide; Female; Glioma; Hematologic Tests; Humans; Male; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Thrombocytopenia; Valproic Acid | 2001 |
Fotemustine plus dacarbazine for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Organophosphorus Compounds; Skin Neoplasms; Thrombocytopenia | 1992 |
Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia | 1992 |
Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
Topics: Adult; Antineoplastic Agents; Digestive System; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Nitrosourea Compounds; Organophosphorus Compounds; Thrombocytopenia | 1987 |